SEC For	m 4																	
FORM 4 UNITED) STA	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Check	this box if no lo	inger subject to	STAT	ГЕМЕ	NT	OF CHANGES IN BENEFICIAL OWNERS							SHIP	OMB Number: 3235-0287				
Section obligat	n 16. Form 4 or ions may contir	Form 5											Estimated average burden hours per response: 0.5					
Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940																		
1. Name and Address of Reporting Person [*] CHAUDHURI BHASKAR						2. Issuer Name and Ticker or Trading Symbol <u>Tarsus Pharmaceuticals</u> , <u>Inc.</u> [TARS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				
(Last) (First) (Middle) C/O TARSUS PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/15/2021												
15440 LAGUNA CANYON ROAD, SUITE 160						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Crown Filing (Chool: Applicable				
					4.1	A in Ameriument, Date of Original Fliet (Month/Day/real)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) IRVINE CA 92618															iled by One Reporting Person iled by More than One Reporting า			
(City) (State) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,			Transaction Disposed Code (Instr. 5)			ities Acquired (A) or d Of (D) (Instr. 3, 4 a		Beneficia Owned F	es F ally (i following (i	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	ransaction code (Instr.)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)			le and of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$35.26	06/15/2021			Α		10,000		(1)	0	6/15/2031	Common Stock	10,000	\$0.00	10,000	D		
Stock Option (right to buy)	\$35.26	06/15/2021			Α		10,000		(2)	0	6/15/2031	Common Stock	10,000	\$0.00	10,000	D		

Explanation of Responses:

1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

2. Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

Remarks:

/s/ Leo Greenstein

** Signature of Reporting Person

06/17/2021 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.